Company intelligence / Profile preview

Oncosence

Ownership: Private
Development stage: Preclinical

Overview

Oncosence is developing small molecule drugs that selectively induce cellular senescence in cancer cells and then clear these cells using senolytic agents. This two-step approach aims to halt tumor growth by first driving malignant cells into a non-dividing state, then eliminating them to prevent tumor progression or metastasis. No clinical results have been published as of now.

Therapeutic areas: Oncology
Modalities: Small moleculeSenescence-inducing compoundSenolytic agent
Industry: Biotech

Beyond the preview

Go deeper on Oncosence.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oncosence.

Explore the full profile